References:
1. Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D, et al. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2022.2. Bonacina E, Armengol-Alsina M, Hurtado I, Garcia-Manau P, Ferrer-Oliveras R, Monreal S, et al. sFlt-1 to PlGF ratio cut-offs to predict adverse pregnancy outcomes in early-onset FGR and SGA: a prospective observational study. J Obstet Gynaecol. 2022:1-6.3. Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8.4. Wang A, Holston AM, Yu KF, Zhang J, Toporsian M, Karumanchi SA, et al. Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. J Matern Fetal Neonatal Med. 2012;25(8):1447-52.5. Kingdom J, Ashwal E, Lausman A, Liauw J, Soliman N, Figueiro-Filho E, et al. Guideline No. 442: Fetal Growth Restriction: Screening, Diagnosis, and Management in Singleton Pregnancies. Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et gynecologie du Canada : JOGC. 2023;45(10):102154.6. Andrikos A, Andrikos D, Schmidt B, Birdir C, Kimmig R, Gellhaus A, et al. Course of the sFlt-1/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery. Archives of gynecology and obstetrics. 2022;305(3):597-605.7. Shinar S, Tigert M, Agrawal S, Parks WA, Kingdom JC. Placental growth factor as a diagnostic tool for placental mediated fetal growth restriction. Pregnancy Hypertens. 2021;25:123-8.8. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333-9.9. Cote ML, Giguere Y, Forest JC, Audibert F, Johnson JA, Okun N, et al. First-Trimester PLGF and PAPP-A and the Risk of Placenta-Mediated Complications: PREDICTION Prospective Study. Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et gynecologie du Canada : JOGC. 2024:102732.10. Agrawal S, Parks WT, Kingdom JC. Uterine and umbilical artery Doppler combined with PlGF assay for placental function expertise in the assessment of fetal growth restriction: a response. Am J Obstet Gynecol. 2022.11. McLaughlin K, Snelgrove JW, Audette MC, Syed A, Hobson SR, Windrim RC, et al. PlGF (Placental Growth Factor) Testing in Clinical Practice: Evidence From a Canadian Tertiary Maternity Referral Center. Hypertension. 2021;77(6):2057-65.12. Yanachkova V, Staynova R, Naseva E, Kamenov Z. The Role of Placental Growth Factor in the Prediction of Carbohydrate and Thyroid Disorders during Pregnancy. Medicina (Kaunas). 2022;58(2).13. McLaughlin K, Hobson SR, Chandran AR, Agrawal S, Windrim RC, Parks WT, et al. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction. Am J Obstet Gynecol. 2022;226(2S):S1145-S56.e1.14. Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and challenges. Am J Obstet Gynecol. 2010;202(6):522-8.15. Ahmed AM, Grandi SM, Pullenayegum E, McDonald SD, Beltempo M, Premji SS, et al. Short-Term and Long-Term Mortality Risk After Preterm Birth. JAMA Netw Open. 2024;7(11):e2445871.16. Agrawal S, Parks WT, Zeng HD, Ravichandran A, Ashwal E, Windrim RC, et al. Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction. Am J Obstet Gynecol. 2022;227(4):618.e1-.e16.17. Anderson N, De Laat M, Benton S, von Dadelszen P, McCowan L. Placental growth factor as an indicator of fetal growth restriction in late-onset small-for-gestational age pregnancies. The Australian & New Zealand journal of obstetrics & gynaecology. 2019;59(1):89-95.18. Noordzij M, Dekker FW, Zoccali C, Jager KJ. Sample size calculations. Nephron Clin Pract. 2011;118(4):c319-23.19. Selvaratnam RJ, Wallace EM, Wolfe R, Anderson PJ, Davey MA. Association Between Iatrogenic Delivery for Suspected Fetal Growth Restriction and Childhood School Outcomes. JAMA. 2021;326(2):145-53.20. Rafique Z, Awan MW, Iqbal S, Usmani NN, Ahmad M, Amjad M, et al. The Ability of Ultrasound Sonography (USG) to Detect Intrauterine Growth Restriction (IUGR) in the Third Trimester of Pregnancy With the Gold Standard of IUGR (Parameters by USG Hadlock) as a Diagnostic Criterion. Cureus. 2021;13(12):e20523.21. Mecacci F, Romani E, Clemenza S, Zullino S, Avagliano L, Petraglia F. Early Fetal Growth Restriction with or Without Hypertensive Disorders: a Clinical Overview. Reprod Sci. 2024;31(3):591-602.22. Dyck R, Klomp H, Tan LK, Turnell RW, Boctor MA. A comparison of rates, risk factors, and outcomes of gestational diabetes between aboriginal and non-aboriginal women in the Saskatoon health district. Diabetes Care. 2002;25(3):487-93.23. Longtine MS, Nelson DM. Placental dysfunction and fetal programming: the importance of placental size, shape, histopathology, and molecular composition. Semin Reprod Med. 2011;29(3):187-96.24. Sibley CP, Turner MA, Cetin I, Ayuk P, Boyd CA, D’Souza SW, et al. Placental phenotypes of intrauterine growth. Pediatr Res. 2005;58(5):827-32.25. . !!! INVALID CITATION !!! 21.26. Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al. FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2021;152 Suppl 1(Suppl 1):3-57.27. Groom KM, McCowan LM, Mackay LK, Lee AC, Said JM, Kane SC, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol. 2017;216(3):296 e1- e14.28. Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One. 2012;7(11):e50208.29. Snowden JM, Klebanoff MA. Accurate identification of cohort study designs in perinatal research: a practical guide. Am J Obstet Gynecol. 2022;227(2):231-5 e1.30. McLaughlin K, Nadeem L, Wat J, Baczyk D, Lye SJ, Kingdom JC. Low molecular weight heparin promotes transcription and release of placental growth factor from endothelial cells. American journal of physiology Heart and circulatory physiology. 2020;318(4):H1008-H17.31. McLaughlin K, Baczyk D, Potts A, Hladunewich M, Parker JD, Kingdom JC. Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia. Hypertension. 2017;69(1):180-8.32. McVicar JA, Orser BA, Wilson CR. No community left behind: advancing rural anesthesia, surgery, and obstetric care in Canada. Can J Anaesth. 2022;69(12):1443-8.33. Lafond G, Haver CRA, Mcleod V, Clarke S, Horsburgh B, Mcleod KM. Characteristics and residence of First Nations patients and their use of health care services in Saskatchewan, Canada: informing First Nations and Métis health services. Journal of Evaluation in Clinical Practice. 2017;23(2):294-300.